RAIN · Rain Oncology Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $61.40M | $15.37M |
| SG&A | $15.74M | $3.59M |
| Total Operating Expenses | $77.14M | $18.96M |
| D&A | $80.0K | $52.0K |
| Operating Income | ($77.14M) | ($18.96M) |
| Interest Expense | - | $135.0K |
| Income Tax | $3.0K | $2.0K |
| Net Income | ($75.72M) | ($21.08M) |
| EPS - Basic | ($2.65) | - |
| EPS - Diluted | ($2.65) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $61.95M | $24.78M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $7.15M | $6.11M |
| Current Assets | $133.63M | $146.15M |
| Total Assets | $135.18M | $147.14M |
| Current Liabilities | $21.97M | $16.32M |
| Long-term Debt | - | - |
| Total Liabilities | $22.14M | $16.64M |
| Stockholders' Equity | $113.04M | $130.50M |
| Retained Earnings | ($165.69M) | ($89.96M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($63.20M) | ($11.23M) |
| Investing Cash Flow | $47.19M | ($5.19M) |
| Financing Cash Flow | $53.18M | $69.49M |
| CapEx | $8.0K | $24.0K |
| Free Cash Flow | ($63.21M) | ($11.26M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | 0.83 | 0.53 |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -56.0% | -14.3% |
| Return on equity | -67.0% | -16.2% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 6.08 | 8.96 |
| Quick ratio | 6.08 | 8.96 |
| Cash ratio | 2.82 | 1.52 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | -140.4x |
| Equity multiplier | 1.20 | 1.13 |
| Liabilities / Assets | 0.16 | 0.11 |
| Efficiency | ||
| Asset turnover | - | - |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -306.9% | - |
| Net income growth (YoY) | -259.2% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -461.6% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -13.4% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Rain Oncology Inc. against the 5 most active filers in the same SIC group.